Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin)

McDonald, GB; Freston, JW; Boyer, JL; DeLeve, LD

McDonald, GB (reprint author), Fred Hutchinson Canc Res Ctr, Gastroenterol Hepatol Sect D5 114, 1100 Fairview Ave North, Seattle, WA 98109 USA.

HEPATOLOGY, 2019; 69 (2): 831

Abstract

Treatment of hematological malignancy with antibody-drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen-expressing......

Full Text Link